相关实验视频

Updated: Feb 17, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

以素为灵感的酸盐混合物作为选择性HDAC6抑制剂,在血液恶性瘤中具有抗增殖活性

Lara Gimenez Borges¹, Thais Nascimento de Oliveira Alves¹, Sandra Valeria Vassiliades¹

¹Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-900, Brazil.

|February 16, 2026

概括

新的二醇-基-酸混合物显示出强大的抗癌活性. 化合物7a和7c可以选择性地抑制HDAC6,显示出作为血液癌症新型治疗剂的前景.

科学领域:

药用化学医学化学
分子生物学分子生物学
计算化学计算化学

背景情况:

基斯脱乙酶6 (HDAC6) 是血液恶性瘤的验证标.
开发选择性HDAC6抑制剂对于最小化非目标效应至关重要.

研究的目的:

合成和评估新的二醇-基-酸混合物作为潜在的抗癌药物.
评估这些化合物的抗增殖活性和HDAC6抑制功效和选择性.

主要方法:

二醇-基-酸混合物的多步合成.
针对血液癌细胞系的体外抗增殖试验 (Jurkat,Namalwa,K-562).
对HDAC6抑制的酶分析,对HDAC1的选择性分析,西部斑点分析,分子对接,动态和ADMET预测的酶分析.

主要成果:

化合物7a和7c表现出显著的抗增殖作用 (IC50 = 3.0-4.5μM).
这两种化合物都在纳米分子范围 (IC50 = 0.007-0.040 μM) 中表现出强有力的和选择性的HDAC6抑制,对HDAC1具有很高的选择性 (>300倍).
通过α-tubulin过乙化证实了目标参与,得到了分子建模和ADMET分析的支持.

结论:

二醇-基-酸混合物,特别是7a和7c,是强效和选择性的HDAC6抑制剂.
这些化合物对血液性瘤细胞具有显著的抗增殖活性.
已识别的杂交物代表了开发新型抗癌疗法的有希望的支架.

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

相关概念视频

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...